Page 3 - Tolerance Network News Today

A clinical trial funded by the National Institutes of Health found that giving peanut...

Very young children most likely to achieve lasting protection

A clinical trial funded by the National Institutes of Health has found peanut oral immunotherapy in children aged 1 to 3 years with severe peanut allergy safely desensitized most children to peanuts and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years. Remission was defined as being able to eat 5 g of peanut protein, without having an allergic reaction six months after completing immunotherapy. The youngest children ...

NIH trial found experimental therapy also reduced most children’s sensitivity to peanut.

The FIANNCIAL — A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years. Remission was defined as being able to eat 5 grams of peanut protein, equivalent to 1.5 tablespoons of peanut butter, without having an allergi...

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1

Landmark NIH allergy study shows immunotherapy successfully desensitizes 71% of young children with severe peanut allergy, with 21% also achieving remission.

After 2.5 years of peanut oral immunotherapy, 71% of toddlers could safely consume 17 peanuts, and more than 1 in 5 maintained this protection even after stopping treatment for 6 months.

It's been a year of fabulous stories - join us on a fascinating journey through our most popular stories of the year.

PAUSE results do not support abatacept for treating psoriatic arthritis, psoriasis skin lesions concurrently Treatment with abatacept was not effective in preventing relapse of psoriasis in patients with moderate-to-severe plaque psoriasis who had been treated with ustekinumab, according to results from the PAUSE study. Researchers concluded that psoriasis, therefore, may rely on different pathways to